- Home
- RCUS vs CRCT Comparison
RCUS vs CRCT Comparison
Compare RCUS & CRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- CRCT
- Stock Information
- Founded
- RCUS 2015
- CRCT 1969
- Country
- RCUS United States
- CRCT United States
- Employees
- RCUS N/A
- CRCT N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- CRCT Wholesale Distributors
- Sector
- RCUS Health Care
- CRCT Industrials
- Exchange
- RCUS Nasdaq
- CRCT Nasdaq
- Market Cap
- RCUS 1.2B
- CRCT N/A
- IPO Year
- RCUS 2018
- CRCT 2021
- Fundamental
- Price
- RCUS $8.17
- CRCT $5.16
- Analyst Decision
- RCUS Strong Buy
- CRCT Sell
- Analyst Count
- RCUS 10
- CRCT 2
- Target Price
- RCUS $29.50
- CRCT $4.78
- AVG Volume (30 Days)
- RCUS 907.7K
- CRCT 405.3K
- Earning Date
- RCUS 05-07-2025
- CRCT 03-04-2025
- Dividend Yield
- RCUS N/A
- CRCT 11.69%
- EPS Growth
- RCUS N/A
- CRCT 20.83
- EPS
- RCUS N/A
- CRCT 0.29
- Revenue
- RCUS $258,000,000.00
- CRCT $712,538,000.00
- Revenue This Year
- RCUS N/A
- CRCT $2.83
- Revenue Next Year
- RCUS $28.07
- CRCT $2.37
- P/E Ratio
- RCUS N/A
- CRCT $18.00
- Revenue Growth
- RCUS 120.51
- CRCT N/A
- 52 Week Low
- RCUS $8.02
- CRCT $4.66
- 52 Week High
- RCUS $18.98
- CRCT $8.40
- Technical
- Relative Strength Index (RSI)
- RCUS 30.17
- CRCT 40.17
- Support Level
- RCUS $8.02
- CRCT $5.10
- Resistance Level
- RCUS $9.19
- CRCT $5.26
- Average True Range (ATR)
- RCUS 0.46
- CRCT 0.18
- MACD
- RCUS 0.01
- CRCT -0.02
- Stochastic Oscillator
- RCUS 7.46
- CRCT 14.29
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.